UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease

American Journal of Hematology

Volumn 83, Issue 3, 2008, Pages 200-202

  Darbari, Deepika S ^a,b   Van Schaik, Ron H N ^c   Capparelli, Edmund V ^d   Rana, Sohail ^e   McCarter, Robert ^f   Van Den Anker, John ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 2B7; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG GLUCURONIDATION; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CLEARANCE; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SICKLE CELL ANEMIA; STATISTICAL ANALYSIS;

ANEMIA, SICKLE CELL; AREA UNDER CURVE; CROSS-SECTIONAL STUDIES; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; LIVER FUNCTION TESTS; METABOLIC CLEARANCE RATE; MORPHINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); VARIATION (GENETICS);

EID: 39749110077     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21051     Document Type: Article

References (10)

1. Graves DA, Arrigo JM, Foster TS, et al. Relationship between plasma morphine concentrations and pharmacologic effects in postoperative patients using patient-controlled analgesia. Clin Pharm 1985;4:41-47.
2. Mather LE. Opioid pharmacokinetics in relation to their effects. Anaesth Intensive Care 1987;15:15-22.
3. Beyer JE. Judging the effectiveness of analgesia for children and adolescents during vaso-occlusive events of sickle cell disease. J Pain Symptom Manage 2000;1:63-72.
4. Gerber N, Apseloff G. Death from a morphine infusion during a sickle cell crisis. J Pediatr 1993;123:322-325.
5. Kopecky EA, Jacobson S, Joshi P, et al. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther 2004;75:140-146.
6. Robieux IC, Kellner JD, Coppes MJ, et al. Analgesia in children with sickle cell crisis: comparison of intermittent opioid vs. continuous intravenous infusion of morphine and placebo controlled study of oxygen inhalation. Pediatr Hematol Oncol 1992;4:317-326.
7. Dampier CD, Setty BN, Logan J, et al. Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr 1995;3:461-467.
8. Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997;1:1-4.
9. Holthe M, Rakvag TN, Klepstad P, et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J 2003;3: 17-26.
10. Slawson MH, Crouch DJ, Andrenyak DM, et al. Determination of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in plasma after intravenous and intrathecal morphine administration using HPLC with electrospray ionization and tandem mass. J Anal Toxicol 1999;23:468-473.